ScreenerHero

CNTX Context Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · contexttherapeutics.com
0.3126USD-2.86%Mkt Cap: 28.72M $P/E: —

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap28.72M USD
Enterprise Value-13.18M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-36.12M USD
Revenue/Share—
Last Price0.3126 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees15
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.74
PEG—
EV/EBITDA0.27
EV/Revenue—
P/S—
P/B0.78
EPS (TTM)-0.45
EPS (Forward)-0.44
52W Range
0.29650% of range3.620
52W High3.620 USD
52W Low0.2965 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-59.73%
ROA-52.74%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-26.39M USD
CapEx (TTM)2.03M USD
FCF Margin—
FCF Yield-109.76%
Net Debt-42.75M USD
Net Debt/EBITDA0.88
Balance Sheet
Debt/Equity0.00
Current Ratio5.81
Quick Ratio5.45
Book Value/Sh0.41 USD
Cash/Share0.47 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)4.032 USD
Upside (mean)+1190.0%
Target Range2.000 USD – 5.000 USD
2.000+1190.0% to mean5.000
# Analysts8
Ownership
Shares Out.91.88M
Float63.73M
Insiders1.57%
Institutions68.81%
Short Interest
Short Ratio3.5d
Short % Float8.67%
Short % Out.7.52%
Shares Short6.91M
Short (prev mo.)6.27M
Technical
SMA 500.4388 (-28.8%)
SMA 2001.564 (-80.0%)
Beta1.72
S&P 52W Chg16.45%
Avg Vol (30d)1.29M
Avg Vol (10d)991.35K
Technical Indicators
RSI (14)34.1
MACD-0.0422
MACD Signal-0.0485
MACD Hist.+0.0062
BB Upper0.4031 USD
BB Middle0.3475 USD
BB Lower0.2919 USD
BB Width31.99%
ATR (14)0.0316 USD
Vol Ratio (20d)0.44x